Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1%
Regulatory Routine −

VVT Med Provides Update on Management Cease Trade Order

Bi-weekly regulatory update on delayed filings and ongoing MCTO restricts insider trading while commercial expansion continues.

By The Northwire Desk — AI Analysis Jun 12, 2026 · 17:00 VVTM · 0.22 VVT Med Inc.
Executive Summary
  • VVT Med Inc. issued a bi-weekly status update regarding a Management Cease Trade Order (MCTO) from the British Columbia Securities Commission (BCSC).
  • The MCTO was originally issued due to continuous disclosure defaults, specifically the delay in filing audited financial statements for the fiscal year ended December 31, 2025.
  • The company anticipates filing the overdue FYE 2025 audited financials and Q1 2026 interim financials by June 29, 2026.
  • The MCTO restricts trading by the CEO and CFO and limits corporate securities transactions with insiders until all required filings are submitted.
  • The company confirms no material changes to prior default announcements and no undisclosed material information.
Material Impact
  • The news is a routine compliance update that confirms the previously communicated June 29, 2026 filing deadline.
  • It does not introduce new commercial catalysts, financial results, or strategic shifts.
  • The MCTO remains in effect, continuing to restrict insider trading and limiting the company's ability to issue securities to insiders/employees, which constrains near-term capital flexibility.
  • Commercial activities (distribution agreements in Italy, Dominican Republic, and US) are proceeding independently, but the regulatory overhang persists without resolution.
VVTM · Price
Company Overview
  • VVT Med Inc. is a medical device company focused on the development and commercialization of the ScleroSafe system, a non-thermal, non-tumescent (NT-NT) solution for treating venous disease (varicose veins).
  • The technology enables controlled sclerosant delivery with simultaneous blood aspiration, eliminating the need for thermal energy or tumescent anesthesia.
  • The company is pursuing a global commercialization strategy through exclusive distribution partnerships, having secured agreements in India, Italy, the Dominican Republic, and the U.S. (via Northwell Health).
  • The company is listed on the TSX Venture Exchange and is in the early stages of scaling its commercial operations.
Read the original news release →

More from VVT Med Inc.

Jun 26, 2026 · 06:45

VVT Med Expands European Commercial Footprint Through Exclusive Distribution Agreement in Greece

Other Jun 11, 2026 · 08:30

Early-stage venous disease device maker scales global distribution while navigating regulatory delays and dilutive capital raises.

Financings May 29, 2026 · 17:32

VVT Med’s Italian Breakthrough Overshadowed as Cease Trade Order Drags Shares to Multi‑Year Lows

Regulatory May 26, 2026 · 08:00

Operational Milestone Achieved Amidst Regulatory Overhang

Production / Operations May 15, 2026 · 17:31

Governance Risks Persist Despite Commercial Traction

Regulatory May 01, 2026 · 19:44

VVT Med Cease Trade Order Halts Financing Flexibility Amidst Commercial Momentum

Regulatory